Modified FOLFIRINOX

Phase 2Small molecule

AbbVie

Modified FOLFIRINOX is one of 90 small molecule programs targeting Pancreas Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreas AdenocarcinomaRecruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Pancreatic CancerRecruiting

Pancreas AdenocarcinomaPhase 2

Recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Pancreatic CancerPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Modified FOLFIRINOX

AbbVie

Phase 2

7 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Active Comparator

Moderna

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06048484

Q3 2027

Phase 2Recruiting

Pancreatic Cancer

NCT06850623

Q1 2029

Phase 1Recruiting

Pancreatic Cancer

NCT06360354

Q3 2029

Phase 2Recruiting

Pancreas Adenocarcinoma

NCT07043270

Clinical

Trials by Indication[1]

Pancreatic Cancer7 trials

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting·OOnconic Therapeutics Inc.·Phase 1·NCT05257993·30 enrolled

Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT03469375·41 enrolled

Show 4 more trials

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

Recruiting·EEXACT Therapeutics AS·Phase 2·NCT06850623·25 enrolled

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Terminated· AbbVie logo

AbbVie·Phase 1·NCT04807972·40 enrolled

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

Completed·EEmory University·Phase 1·NCT01446458·13 enrolled

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Terminated·BBioNTech Research & Development, Inc.·Phase 1·NCT02672917·118 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting·GGulam Manji·Phase 2·NCT06048484·60 enrolled

Adenocarcinoma1 trial

Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT05926206

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·UUniversity of Oklahoma·Phase 1·NCT07829185·30 enrolled

Pancreas Adenocarcinoma1 trial

24BRO681 : Neoadjuvant Therapy With Alternating Gemcitabine Plus Nab-Paclitaxel and mFOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

Recruiting·DDartmouth-Hitchcock Medical Center·Phase 2·NCT07043270·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Modified FOLFIRINOX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Modified FOLFIRINOX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Modified FOLFIRINOX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Modified FOLFIRINOX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q1 2029

Q3 2029

Trials by Indication[1]

Pancreatic Cancer7 trials

Pancreatic Ductal Adenocarcinoma1 trial

Adenocarcinoma1 trial

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

Pancreas Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News